UA108475C2 - Композиція інсуліну тривалої дії - Google Patents
Композиція інсуліну тривалої діїInfo
- Publication number
- UA108475C2 UA108475C2 UAA201202336A UAA201202336A UA108475C2 UA 108475 C2 UA108475 C2 UA 108475C2 UA A201202336 A UAA201202336 A UA A201202336A UA A201202336 A UAA201202336 A UA A201202336A UA 108475 C2 UA108475 C2 UA 108475C2
- Authority
- UA
- Ukraine
- Prior art keywords
- long
- acting insulin
- insulin composition
- insulin compound
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Abstract
Винахід стосується фармацевтичної композиції, що містить сполуку інсуліну в концентрації щонайменше 10 мг/мл, яка характеризується тим, що вона має фармакокінетичний профіль in vivo по суті без викиду сполуки інсуліну, при цьому сполука інсуліну повністю міститься в депо-препараті.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09167017 | 2009-07-31 | ||
EP09179337 | 2009-12-15 | ||
EP09179827 | 2009-12-18 | ||
PCT/EP2010/061160 WO2011012719A1 (en) | 2009-07-31 | 2010-07-30 | Long acting insulin composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UA108475C2 true UA108475C2 (uk) | 2015-05-12 |
Family
ID=43033453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201202336A UA108475C2 (uk) | 2009-07-31 | 2010-07-30 | Композиція інсуліну тривалої дії |
Country Status (29)
Country | Link |
---|---|
US (1) | US9265723B2 (uk) |
EP (1) | EP2459171B1 (uk) |
JP (1) | JP5732053B2 (uk) |
KR (1) | KR101759499B1 (uk) |
CN (1) | CN102625695B (uk) |
AU (1) | AU2010277560B2 (uk) |
BR (1) | BR112012001988A2 (uk) |
CA (1) | CA2769540C (uk) |
CL (1) | CL2012000469A1 (uk) |
CO (1) | CO6491085A2 (uk) |
CR (1) | CR20120019A (uk) |
DK (1) | DK2459171T3 (uk) |
EC (1) | ECSP12011631A (uk) |
ES (1) | ES2636741T3 (uk) |
GT (1) | GT201200020A (uk) |
IL (1) | IL217613A (uk) |
MA (1) | MA33466B1 (uk) |
MX (1) | MX2012001141A (uk) |
NI (1) | NI201200013A (uk) |
NZ (1) | NZ597964A (uk) |
PE (1) | PE20121170A1 (uk) |
PL (1) | PL2459171T3 (uk) |
PT (1) | PT2459171T (uk) |
RU (1) | RU2556340C2 (uk) |
SG (1) | SG178195A1 (uk) |
TN (1) | TN2012000010A1 (uk) |
UA (1) | UA108475C2 (uk) |
WO (1) | WO2011012719A1 (uk) |
ZA (1) | ZA201200224B (uk) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0507875B8 (pt) * | 2004-03-23 | 2021-05-25 | Complex Biosystems Gmbh | pró-fármaco de cascata polimérico |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
UA108475C2 (uk) | 2009-07-31 | 2015-05-12 | Санофі-Авентіс Дойчланд Гмбх | Композиція інсуліну тривалої дії |
MX2012001399A (es) | 2009-07-31 | 2012-03-21 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector. |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
AU2012216648C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
AU2012346058A1 (en) * | 2011-11-28 | 2014-06-12 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents comprising insulin amino acid sequences |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US20150231334A1 (en) * | 2013-12-18 | 2015-08-20 | Windgap Medical, Inc. | Drug mixing and delivery system and method |
DK2983697T3 (en) | 2013-04-03 | 2019-02-25 | Sanofi Sa | TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN |
TW201609145A (zh) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋(depot)之方法 |
JP2020143105A (ja) * | 2014-01-09 | 2020-09-10 | サノフイSanofi | インスリンアスパルトの安定化された医薬製剤 |
BR112016015851A2 (pt) * | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
MX2016008979A (es) * | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
JP2020114861A (ja) * | 2014-01-09 | 2020-07-30 | サノフイSanofi | インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤 |
CN105899191B (zh) * | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
JP7173953B2 (ja) * | 2014-01-09 | 2022-11-16 | サノフイ | インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤 |
AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
CN103830189A (zh) * | 2014-03-04 | 2014-06-04 | 山东新时代药业有限公司 | 一种重组甘精胰岛素制剂及其制备方法 |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
WO2016100949A2 (en) | 2014-12-18 | 2016-06-23 | Windgap Medical, Inc. | Method and compositions for dissolving or solubilizing therapeutic agents |
CN105796508A (zh) * | 2014-12-30 | 2016-07-27 | 江苏万邦生化医药股份有限公司 | 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CA3015585A1 (en) | 2016-03-01 | 2017-09-08 | Ascendis Pharma Bone Diseases A/S | Pth prodrugs |
EP3515408A1 (en) | 2016-09-23 | 2019-07-31 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
CN117838873A (zh) * | 2016-09-29 | 2024-04-09 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
AU2017336251B2 (en) * | 2016-09-29 | 2024-02-22 | Ascendis Pharma Bone Diseases A/S | PTH compounds with low peak-to-trough ratios |
US10869851B1 (en) * | 2017-03-13 | 2020-12-22 | The United States Government As Represented By The Secretary Of The Army | Targeting NUR77 for mitigating perinatal neuroinflammation |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
CN111050750A (zh) | 2017-08-24 | 2020-04-21 | 诺沃挪第克公司 | Glp-1组合物及其用途 |
TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣3多肽之持續遞送 |
WO2021034727A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
EP4106727A1 (en) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
US5634943A (en) | 1990-07-12 | 1997-06-03 | University Of Miami | Injectable polyethylene oxide gel implant and method for production |
WO1993017669A1 (en) | 1992-02-28 | 1993-09-16 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
DE19626762A1 (de) | 1996-07-03 | 1998-01-08 | Basf Ag | Enzymatisch spaltbare Linker für Festphasensynthesen |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
DE69838916T2 (de) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | Neuartige exendin agonisten |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
ES2211033T3 (es) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos. |
DE69936446T2 (de) | 1998-02-13 | 2008-03-06 | Amylin Pharmaceuticals, Inc., San Diego | Inotropische und diuretische effekte von exendin und glp-1 |
WO2000021572A2 (en) | 1998-10-09 | 2000-04-20 | The University Of Michigan | Hydrogels and water soluble polymeric carriers for drug delivery |
JP2002531217A (ja) | 1998-12-04 | 2002-09-24 | チャンドラシェカー ピー. パサック, | 生体適合性架橋ポリマー |
ES2368988T3 (es) | 1999-02-01 | 2011-11-24 | Eidgenössische Technische Hochschule Zürich | Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados. |
JP4217004B2 (ja) | 1999-05-17 | 2009-01-28 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 血液成分への結合体化を介するペプチダーゼ活性からの内因性治療用ペプチドの保護 |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
AU1249001A (en) | 1999-06-11 | 2001-01-31 | Nektar Therapeutics Al, Corporation | Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
US6372813B1 (en) | 1999-06-25 | 2002-04-16 | Motorola | Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001055360A1 (en) | 2000-01-28 | 2001-08-02 | Infimed Therapeutics, Inc. | Slow release protein polymers |
US6884778B2 (en) | 2000-04-14 | 2005-04-26 | William Marsh Rice University | Biocompatible macromers |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP4841066B2 (ja) | 2000-09-01 | 2011-12-21 | ライスユニバーシティ | 酸化窒素生成ヒドロゲル物質 |
US6537569B2 (en) | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
JP4340067B2 (ja) | 2001-04-23 | 2009-10-07 | ウィスコンシン アルムニ リサーチ ファウンデイション | 二機能性改変ハイドロゲル |
CN1314445C (zh) | 2001-05-21 | 2007-05-09 | 耐科塔医药公司 | 化学修饰胰岛素的肺部给药 |
ATE381963T1 (de) | 2001-10-26 | 2008-01-15 | Octoplus Technologies B V | Verfahren zur herstellung von gereinigten partikeln |
US6960298B2 (en) | 2001-12-10 | 2005-11-01 | Nanogen, Inc. | Mesoporous permeation layers for use on active electronic matrix devices |
US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
EP1494757A2 (en) | 2002-04-04 | 2005-01-12 | Enzon, Inc. | Polymeric acyl derivatives of indoles |
DE10221457A1 (de) | 2002-05-15 | 2003-11-27 | Behr Gmbh & Co | Wärmeübertrager und Verfahren zu seiner Herstellung |
CA2487720A1 (en) | 2002-06-03 | 2003-12-11 | Alnis Biosciences, Inc. | Therapeutic agent-containing polymeric nanoarticles |
JP2005528913A (ja) | 2002-06-10 | 2005-09-29 | メルク エンド カムパニー インコーポレーテッド | 新規動原体関連モータータンパク質をコードする単離核酸分子及びその使用 |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
CA2506080A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
LT2644206T (lt) | 2003-05-23 | 2019-05-27 | Nektar Therapeutics | Peg dariniai, susidedantys iš dviejų peg grandinių |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
BRPI0507875B8 (pt) * | 2004-03-23 | 2021-05-25 | Complex Biosystems Gmbh | pró-fármaco de cascata polimérico |
EP1586334A1 (en) | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
JPWO2006038462A1 (ja) | 2004-10-01 | 2008-05-15 | 国立大学法人九州大学 | 新規ステロイド産生細胞 |
DE102004051715A1 (de) | 2004-10-23 | 2005-06-30 | Clariant Gmbh | Flüssigwaschmittel enthaltend Farbfixiermittel |
US7678551B2 (en) | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
US20060115865A1 (en) | 2004-10-25 | 2006-06-01 | Anlong Ouyang | Lamotrigine analogs |
US7407117B2 (en) | 2004-10-28 | 2008-08-05 | Meadwestvaco Calmar, Inc. | Liquid sprayer assembly |
JP2006163996A (ja) | 2004-12-09 | 2006-06-22 | Evolium Sas | 行動履歴に基づくプッシュ型の情報提供システム |
EP1838317A4 (en) | 2005-01-05 | 2012-02-29 | Univ Minnesota | ANALGESIC CONJUGATES |
KR100665672B1 (ko) | 2005-04-13 | 2007-01-09 | 성균관대학교산학협력단 | 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
US8070810B2 (en) | 2006-01-12 | 2011-12-06 | Histogenics Corporation | Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries |
EP1840152B1 (en) | 2006-03-31 | 2009-07-08 | Sony Deutschland Gmbh | A method of forming a crosslinked polymer gel |
AU2007267550A1 (en) | 2006-05-25 | 2007-12-06 | The General Hospital Corporation | Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations |
JP5550338B2 (ja) | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー/エス | ペグ化持続型インスリン |
JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
GB0619175D0 (en) | 2006-09-29 | 2006-11-08 | Univ Nottingham | Polymer |
CN101541857B (zh) | 2006-11-27 | 2012-12-12 | 阿克塔马克斯手术器材有限责任公司 | 多官能聚环氧烷、水凝胶和组织粘合剂 |
AU2008214319A1 (en) | 2007-02-06 | 2008-08-14 | Incept, Llc | Polymerization with precipitation of proteins for elution in physiological solution |
US20080220047A1 (en) | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
WO2008116913A2 (en) | 2007-03-28 | 2008-10-02 | Novo Nordisk A/S | Peptide compounds with transient biodegradable pegylation |
CN101711168B (zh) | 2007-04-13 | 2013-05-01 | 库罗斯生物外科股份公司 | 聚合物组织封闭剂 |
EP2152243A2 (en) * | 2007-04-30 | 2010-02-17 | Novo Nordisk A/S | Highly concentrated insulin solutions and compositions |
WO2008148839A2 (en) * | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
US20100216691A1 (en) | 2007-07-16 | 2010-08-26 | Novo Nordisk A/S | Protease Stabilized, Pegylated Insulin Analogues |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
ES2733355T3 (es) | 2008-02-01 | 2019-11-28 | Ascendis Pharma As | Profármaco que comprende un enlazador autoescindible |
JP5739668B2 (ja) | 2008-02-13 | 2015-06-24 | ハイパーブランチ メディカル テクノロジー, インコーポレイテッド | 調節可能な分解速度を有する架橋ポリアルキレンイミンヒドロゲル |
AU2009241847B2 (en) | 2008-04-28 | 2014-07-10 | Zogenix, Inc. | Novel formulations for treatment of migraine |
EP3050576B1 (en) | 2008-04-29 | 2021-03-31 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
US20120058084A1 (en) | 2009-03-05 | 2012-03-08 | Ascendis Pharma As | Interferon Alpha Carrier Prodrugs |
UA108475C2 (uk) | 2009-07-31 | 2015-05-12 | Санофі-Авентіс Дойчланд Гмбх | Композиція інсуліну тривалої дії |
EP3782649A1 (en) | 2009-07-31 | 2021-02-24 | Ascendis Pharma A/S | Biodegradable polyethylene glycol based water-insoluble hydrogels |
MX2012001399A (es) | 2009-07-31 | 2012-03-21 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector. |
AU2010311421B2 (en) | 2009-10-29 | 2014-11-20 | Ascendis Pharma A/S | Sterilization of biodegradable hydrogels |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
-
2010
- 2010-07-30 UA UAA201202336A patent/UA108475C2/uk unknown
- 2010-07-30 CN CN201080044021.3A patent/CN102625695B/zh not_active Expired - Fee Related
- 2010-07-30 BR BR112012001988A patent/BR112012001988A2/pt not_active Application Discontinuation
- 2010-07-30 EP EP10736745.0A patent/EP2459171B1/en active Active
- 2010-07-30 JP JP2012522189A patent/JP5732053B2/ja active Active
- 2010-07-30 CA CA2769540A patent/CA2769540C/en not_active Expired - Fee Related
- 2010-07-30 WO PCT/EP2010/061160 patent/WO2011012719A1/en active Application Filing
- 2010-07-30 KR KR1020127005593A patent/KR101759499B1/ko active IP Right Grant
- 2010-07-30 DK DK10736745.0T patent/DK2459171T3/en active
- 2010-07-30 ES ES10736745.0T patent/ES2636741T3/es active Active
- 2010-07-30 PL PL10736745T patent/PL2459171T3/pl unknown
- 2010-07-30 MA MA34581A patent/MA33466B1/fr unknown
- 2010-07-30 SG SG2012006847A patent/SG178195A1/en unknown
- 2010-07-30 US US13/387,959 patent/US9265723B2/en not_active Expired - Fee Related
- 2010-07-30 RU RU2012107487/15A patent/RU2556340C2/ru not_active IP Right Cessation
- 2010-07-30 MX MX2012001141A patent/MX2012001141A/es active IP Right Grant
- 2010-07-30 NZ NZ597964A patent/NZ597964A/en not_active IP Right Cessation
- 2010-07-30 PT PT107367450T patent/PT2459171T/pt unknown
- 2010-07-30 PE PE2012000135A patent/PE20121170A1/es not_active Application Discontinuation
- 2010-07-30 AU AU2010277560A patent/AU2010277560B2/en not_active Ceased
-
2012
- 2012-01-05 TN TNP2012000010A patent/TN2012000010A1/en unknown
- 2012-01-11 ZA ZA2012/00224A patent/ZA201200224B/en unknown
- 2012-01-12 CR CR20120019A patent/CR20120019A/es unknown
- 2012-01-18 IL IL217613A patent/IL217613A/en not_active IP Right Cessation
- 2012-01-25 NI NI201200013A patent/NI201200013A/es unknown
- 2012-01-26 GT GT201200020A patent/GT201200020A/es unknown
- 2012-01-26 CO CO12011796A patent/CO6491085A2/es active IP Right Grant
- 2012-01-30 EC EC2012011631A patent/ECSP12011631A/es unknown
- 2012-02-23 CL CL2012000469A patent/CL2012000469A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA108475C2 (uk) | Композиція інсуліну тривалої дії | |
PH12016500606A1 (en) | Insulin preparations containing methionine | |
NZ599848A (en) | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine | |
EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
MX2009005797A (es) | Derivado de acido carboxilico. | |
HK1131978A1 (en) | Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof | |
TN2012000248A1 (en) | Novel spiropiperidine compounds | |
SI2379511T1 (sl) | Substituirani diketopiperazinski analogi za uporabo kot sredstva za dostavo zdravil | |
NZ609309A (en) | Redox drug derivatives | |
MY159565A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
UA105042C2 (uk) | Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання | |
MX348654B (es) | Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion. | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
HK1145631A1 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
EA201270216A1 (ru) | Фармацевтический состав | |
PT2080501E (pt) | Solução de fármaco tendo um teor reduzido de oxigénio dissolvido, método de produção da mesma e unidade para conter a solução de fármaco tendo um teor reduzido de oxigénio dissolvido | |
WO2007095631A3 (en) | New drug delivery system for crossing the blood brain barrier | |
EA201171497A1 (ru) | Снижение флуктуаций опиоидов в крови | |
TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
EP2150235A4 (en) | Capsule formulation coated with nanoparticles for the purpose of dermal drug administration | |
WO2009037586A3 (en) | Use of peptidic vasopressin receptor agonists | |
SI2004149T1 (sl) | Farmacevtski sestavki ki vsebujejo leflunomid | |
WO2009121946A3 (en) | Process for the preparation of optically enriched clopidogrel |